Tagged as: Byooviz

Biogen Launches BYOOVIZ (ranibizumab) in Canada

On March 1, 2023, Biogen Canada Inc. announced that BYOOVIZTM (ranibizumab injection), a biosimilar to Genentech’s LUCENTIS, is now available in Canada.  BYOOVIZ is an anti-VEGF (vascular endothelial growth factor) therapy approved for the treatment of various eye disorders, including neovascular age-related macular degeneration (AMD).  According to Biogen, AMD accounts…

Read More